News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Nicorette Sales Increase In Lead Up to December 10

Nicorette Sales Increase In Lead Up to December 10 Smoke-free

Sales of New Zealand’s leading nicotine replacement therapy (NRT)1 – Nicorette – have grown as the December 10 deadline for smoke-free workplaces draws nearer.

Nicorette spokesman, Peter Baltus, says overall sales of Nicorette – which includes gum, patch, inhaler and now the new Microtab – have grown by more than 20% in the last six months, with the sharpest growth being experienced from August as smokers gear up for the legislation change.

“While some of this growth can be attributed to an advertising campaign which began in May and the launch of a new product, we believe that many smokers are using this historic health milestone to take up the challenge to quit,” said Mr Baltus.

The Nicorette brand now accounts for around 30% of the dollar value of the NRT market in New Zealand.

In addition Pfizer, which markets and distributes Nicorette has also experienced a 37% growth in its NRT category sales through pharmacies, compared to an overall industry category growth of just 9%.

The company recently launched a new form of Nicorette called Nicorette Microtab – a small, discreet tablet which is placed under the tongue – which the company expects will make it easier for smokers to forgo a cigarette while out socialising.

“The uptake of Nicorette Microtab has been fantastic with most pharmacies purchasing stock of the new product. We have sold nearly 8,000 units in the first few weeks,” said Mr Baltus.

Meanwhile, Nicorette has also been working closely with organisations such as SCANZ – Sporting Clubs Association of New Zealand – to help its members be better prepared for the changes to the Smoke-free Environments Act. The company has offered members, along with nearly 100 other clubs, bars, restaurants and RSAs a 12-week information programme offering advice and motivational help to plan for the changeover.

At the same time the company has confirmed a distribution contract with Gilmours to enable these sorts of venues to sell Nicorette gum and patches “over the bar” for the first time in this country’s history.

“Orders are starting to roll in. We expect many smokers will choose to use Nicorette when they are out at sports clubs and bars as a way to delay the urge for a cigarette. If these people can also be encouraged to quit altogether that is even better,” said Mr Baltus.

“If you are planning to quit smoking, nicotine replacement therapy (NRT) is an effective way to do it.2 It is the most widely used, clinically proven treatment for tobacco dependence.3 “

It is proven with Nicorette a smoker is twice as likely to succeed in quitting compared to willpower alone2, making it even easier to say no to cigarettes.

NRT works by releasing just enough nicotine into your body to wean you off cigarettes, relieving the cravings when they happen and helping you break the habit.

There are many brands of NRT in New Zealand - the most well known is Nicorette4.

Nicorette also offers a 12-week ‘Steps to Success’ programme to help people stay on track with their goal to quit smoking, this includes a support line: 0800 SAY NO NOW (0800 729 666).

References: Aztec MAT Value, July 2004 Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation (review). Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 1, 2001, Oxford: Update Software Garvey AJ et al. Nicotine & Tobacco Research 2000; 2:53:63 Pfizer Consumer Research, December 2003.

Nicorette is a stop smoking aid. Nicorette Gum contains 2mg and 4mg nicotine. Nicorette Patch delivers 15mg, 10mg and 5mg nicotine over 16 hours. Nicorette Inhaler is a Pharmacy Only Medicine containing 10mg Nicotine. Nicorette Microtab is a Pharmacy Only Medicine containing 2mg Nicotine. Medicines have benefits and some may have risks. Always read the label carefully and use strictly as directed. If you have any side effects, or require further information, consult your doctor or pharmacist. Pfizer Consumer Healthcare, Auckland.

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis: Joel Coen's Monochromatic Macbeth

The Bard of Avon may well be smirking up the sleeves of his lace doublet at the irony of Will Smith's Oscar debacle, but now that the initial furore has dissipated, it's worth revisiting the movie for which Denzel Washington was also nominated. More>>

Howard Davis: Kenneth Branagh’s Black & White Belfast

Branagh has assembled a wonderful cast, including Ciarán Hinds, a gently formidable actor who well deserves his Oscar nomination, and Judi Dench, who steals every scene she’s in. More>>


Howard Davis: Dennis Villeneuve’s Dune - A Brief History

So many elements of Herbert’s novel have since become tropes of popular SciFi that Villeneuve’s film sometimes seems deceptively derivative. What makes all this nonsense essential viewing is his astonishing visual sensibility. More>>


Howard Davis: Jill Trevelyan's Rita Angus

Although Angus has become one of Aotearoa’s best-loved painters, the story of her life remained little known and poorly understood before Jill Trevelyan's acclaimed and revelatory biography, which has been republished by Te Papa press. More>>

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland